Last updated: April 23, 2026
Baclofen is a widely supplied generic muscle relaxant. Across the value chain, suppliers fall into two practical buckets: (1) API and (2) finished dosage manufacturers (tablets) and packaging/distribution intermediaries. The supply landscape is broad, with multiple China- and India-based API producers and multiple branded/generic tablet manufacturers worldwide.
Which companies supply baclofen API?
Baclofen API supply is typically provided by chemical manufacturers that sell through bulk API contracts to finished-dose manufacturers and repackagers. The most commonly encountered API supplier names in the market include:
- Hubei Wanbang Pharmaceutical Co., Ltd. (China)
- Zhejiang Jiahe Pharma Co., Ltd. (China)
- Hebei Xinji Pharmaceutical Co., Ltd. (China)
- Lianyungang Tianyi Pharmaceutical Co., Ltd. (China)
- Shandong Kangyuan Pharma (China)
- Matsuno? (No confirmed supplier mapping in standard catalogs from available data)
API specification expectation in procurement: suppliers typically provide baclofen API with controlled polymorph/particle-size or solid form controls (where applicable), plus a regulatory pack containing CoA, typical GMP compliance evidence, and standard quality documentation (DMF/CEP where held).
Which companies supply finished baclofen tablets?
Finished dosage supply depends on country, tender cycles, and inclusion in national formularies. In practice, baclofen tablet brands/generics are produced by multiple global generic manufacturers.
Common finished-dose producers that appear in national and international generic markets include:
- Sandoz (broad generic portfolio; baclofen generics in multiple markets)
- Teva (generic CNS lineup; baclofen tablets in multiple geographies)
- Mylan/Viatris (generic portfolio; baclofen availability by market)
- Accord Healthcare (EU/UK-focused generic supplier; baclofen in multiple tenders)
- Torrent Pharmaceuticals (India; baclofen tablets in multiple export channels)
- Sun Pharma (India; generic baclofen supply footprint)
Finished-dose sourcing is usually brokered via local wholesalers and tender-specific distributors, with API traceability back to the API manufacturer stated on batch records.
What supplier categories matter for procurement?
Procurement typically needs supplier classification because the risk and compliance burden differ:
- API manufacturers
- Supply baclofen API directly to finished-dose manufacturers.
- Finished-dose manufacturers (FDF)
- Manufacture and release baclofen tablets under finished product GMP.
- Importers and distributors
- Handle logistics, local compliance, pharmacovigilance coordination, and wholesaler distribution.
What documents should you require from baclofen suppliers?
For reliable sourcing, baclofen supplier audits and onboarding typically require the same core documentation set:
- Certificate of Analysis (CoA) for each batch (tests and acceptance criteria)
- GMP evidence for the manufacturing site
- Quality Agreement covering change control, deviations, CAPA escalation, and complaint handling
- Stability data for finished dosage (shelf-life support)
- Analytical methods (in-house methods or cross-reference to pharmacopeial standards)
- Regulatory status evidence where required (DMF/CEP/filings per region)
How do regional markets affect supplier choice?
Baclofen supply differs by region due to:
- Local generic tendering and reimbursement rules
- Approved product dossiers and site licensing
- Export channel structure (API sold globally; FDF often routed through region-specific distributors)
In the US/EU, finished products generally come from companies with established local registrations and tender presence. In export-oriented pipelines, API sellers from China and India commonly feed multiple FDF players.
Supplier due diligence checklist for baclofen
Use this checklist to narrow supplier candidates from the long list of catalog sources:
- GMP coverage: verify the API or FDF site has relevant GMP scope for baclofen
- Batch consistency: confirm repeatable impurity profiles, especially for:
- Known related substances
- Residual solvents and elemental impurities (region dependent)
- Solid form control (as applicable): confirm any polymorph/particle-size controls if specified in the dossier
- Supply reliability: confirm lead times and historical on-time delivery
- Regulatory alignment: confirm dossier linkage to region requirements (US DMF, EU CEP, or equivalent)
- Complaint history: request CAPA summaries related to baclofen quality issues (if available through onboarding)
Where does demand concentrate in baclofen supply?
Demand concentrates in:
- Generic oral tablet supply (most recurring volume)
- CNS/muscle relaxant portfolio manufacturing for generic houses
- Tender-driven procurement in EU markets and distributor-led supply in other regions
Baclofen is mature enough that supplier lists are stable and competition is driven by:
- price-to-spec adherence,
- regulatory compliance record,
- and ability to maintain consistent impurity and dissolution performance (for FDF).
Key Takeaways
- Baclofen has a broad global supplier base with multiple API manufacturers (predominantly China/India) feeding numerous finished-dose manufacturers that sell across regions.
- Supplier selection should be driven by GMP scope, CoA/analytical package completeness, and documented change-control and deviation handling, not by catalog availability.
- For procurement, the highest leverage is in verifying batch-to-batch quality consistency (API impurity profile and FDF dissolution/assay consistency), plus regulatory dossier linkage for the target market.
FAQs
1) Are baclofen API and baclofen tablets sourced from the same companies?
Often no. API producers sell to multiple finished-dose manufacturers, and FDF releases rely on finished product GMP and region-specific approvals.
2) What is the most common finished form for baclofen supply?
Oral immediate-release tablets dominate procurement in most markets.
3) Why does supplier qualification matter more for generics than for branded drugs?
Because generic FDF performance (assay, impurities, dissolution) and API impurity control directly determine batch acceptability for bioequivalence-related submissions and tenders.
4) What documents are essential during onboarding?
At minimum: CoA, GMP evidence, quality agreement, and region-appropriate regulatory evidence (DMF/CEP or equivalent) tied to the marketed product.
5) What supplier risk shows up most often in baclofen supply chains?
Quality and regulatory mismatch: inconsistent impurity profile from API, or dissolution/assay variability from FDF manufacturing changes not reflected in dossier control.
References
[1] FDA. (n.d.). Drug Shortages. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-shortages
[2] EMA. (n.d.). European Medicines Agency: Human medicines. European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory-overview
[3] USP. (n.d.). USP–NF. United States Pharmacopeia. https://www.uspnf.com/
[4] WHO. (n.d.). WHO Global Surveillance and Monitoring System. World Health Organization. https://www.who.int/teams/regulation-prequalification/incidents-and-safety-management/safety-monitoring-and-surveillance
